Background: The management of sinonasal undifferentiated carcinoma (SNUC) remains unclear. Low incidence and poor outcomes make treatment standardization difficult. The objective of this study was to review the used treatment and our outcomes.
Introduction
The World Health Organization defined SNUC as a highly aggressive and clinicopathologically distinct carcinoma of uncertain histogenesis that typically presents with locally extensive disease. It is composed of pleomorphic tumour cells with frequent necrosis, and should be differentiated from lymphoepithelial carcinoma and olfactory neuroblastoma (1) .
Despite that its origin remains unclear, there is increasing evidence that SNUC is a surface (Schneiderian) epithelial-derived malignancy, with or without concurrent neuroendocrine differentiation (2) . Differential diagnosis is wide because a range of similar lesions with an undifferentiated or poorly differentiated morphology may occur at this site. However, histology, immunohistochemistry or molecular biology is becoming increasingly important for choosing an appropriate treatment strategy (3) . SNUC presents as a rapidly enlarging tumour with initially vague symptoms that are of relatively short duration. SNUC tends to be locally advanced upon presentation, and orbital, dural, or intracranial invasion are frequent. SNUC has the ability to spread regionally (30%) and with distant metastasis. SNUC is reputed to be refractory to even the most radical therapy and to carry a poor prognosis, particularly when the tumour transgresses the skull base.
C o r r e c t e d p r o o f
Since its initial description in 1986, a number of case studies and small case series, with numbers ranging from 10 to 20 patients, have been reported in the literature examining outcomes in this disease, and treatment decisions are guided by these published small series. Only 167 cases have been reported in a recent meta-analysis (5) . Comparisons of outcomes of different studies have also been limited by the heterogeneous disease patterns and varying treatment regimens used.
Early reports on radiation or surgical resection alone have generally yielded poor results (6) . A combination of radical surgery, chemotherapy and radiotherapy (RT) appears to provide the best chance of survival, but there is still no consensus about which modalities to use and the best sequence (3) . Nevertheless, given the aggressive nature of this disease and the poor specificity in symptom presentation, the prognosis is poor, the recurrence is frequent and overall mortality is high (4) . Examination of data across studies looking at treatment modalities may yield important trends that will help guide modern decision making in such a rare and aggressive disease.
The aim of the current study is to present the experience in the management of this tumour at our tertiary care academic teaching hospital. Moreover, we analyse the relevant previously published experience from the initial description in 1986 of this tumour.
Materials and Methods

Chart review
The surgical medical charts of the Otorhinolaryngology Department of our hospital, from 2001 to January 2013, were reviewed to collect data regarding the clinical data of patients diagnosed with SNUC. The methodology was a retrospective, non-randomized chart review. We identified 17 patients diagnosed of SNUC ( Figure 1 ). No patients with this diagnosis were initially treated with palliative care during the study time period. All patients gave their signed informed consent, and the study had received prior approval from the ethics committee of our institution.
Data collection was based on a review of the patients' medical histories, recorded data on age, tumour size, location, presenting symptoms, treatment modalities (surgical procedures, chemotherapy and RT), pathological findings, treatment complications, recurrence and status at last follow-up visit. Extent of the tumour was determined by evaluation of patient´s paranasal computed tomography (CT) and/or and magnetic resonance imaging (MRI). The data describe the extent of disease through surgical description, radiography, International Union Against Cancer (UICC) staging, and Kadish staging. CT scan showed erosion of the skull base and MRI scans were useful to demonstrate the intracranial and intraorbital extension. The pathology on all patients was reviewed at our institution to confirm the diagnosis of SNUC, according Franchi et al. (3) criteria. Based on the joint recommendations of multidisciplinary head and neck conference, patients were selected for treatment with surgery followed by chemoradiotherapy, induction chemotherapy followed by surgery and chemoradiotherapy, or definitive chemoradiotherapy.
All patients were treated with curative intent and the goal of surgery was complete resection of tumour with negative margins, with as low morbidity as possible. Craniofacial resection was performed in all cases. Orbital exenteration was not an elective procedure but mandatory in patients with tumour invasion beyond the periorbital tissue. Criteria for unresectability were extensive intradural spread, invasion of the optic pathway, invasion of cavernous sinus, and encasement of the carotid artery.
The follow-up consisted of periodic visits to our clinic. A CT and/ or MRI were performed annually in all patients for the first 5 years of follow-up. Duration of control was calculated from the date of finishing the last treatment modality.
Statistical Analysis
Fisher's exact test was used for comparison. Survival curves were calculated by the Kaplan-Meier method and the comparison between subgroups was performed by Log Rank test. A P value of < 0.05 was considered statistically significant. All calculations were performed using SPSS 19.0 for Windows.
Results
Clinic characteristics
The patients' characteristics are shown in Table 1 . The tumour 
Treatment
The summary of the treatment modalities used are shown in Table 2 . The preferred treatment was craniofacial resection followed by postoperative chemoradiotherapy (82% of patients).
We maintained a relatively aggressive posture toward surgical resection. However, in 3 patients the tumour was initially deemed unresectable because of its large size and its extensive orbit and intradural involvement, so these patients received induction chemotherapy; then they underwent craniofacial resection followed by postoperative chemoradiotherapy. One patient who underwent craniofacial resection declined postoperative chemotherapy and was thus treated with postoperative RT alone. The 5 last patients were operated on by endoscopic craniofacial resection as previously reported (7) . Orbital exenteration was combined with craniofacial resection in 5 patients. All patients who underwent resection had all gross tumour removed. Intraoperative frozen section was used to achieve tumour-free margins. Finally, definitive concurrent chemoradiotherapy was used to treat 3 pa- As describe above, all patients in our series received RT.
Fourteen patients (82%) were treated with 3-dimensional conformal RT (3DCRT), and intensity-modulated radiotherapy (IMRT) was used to treat the remaining 3 patients (18%). RT was given at a total dose of 64-72 Gy in 2-Gy fractions daily. There were no breaks in treatment due to acute radiation toxicities.
According to the local protocol for the treatment of paranasal sinus cancers, bilateral elective nodal irradiation (ENI) was advocated in high-risk node-negative patients with involvement of the skin of the cheek, infratemporal fossa, pterygoid region, nasopharynx or cribriform plate. Of 15 patients with a clinically negative neck, 10 patients received ENI and 5 patients did not receive elective treatment. The remaining patients with clinically positive nodes received a modified radical neck dissection and RT to the regional disease.
Outcomes
Disease control
Six patients (35%) developed recurrences an average of 10 months after presentation or treatment (range 3 to 24 months) (Table 3) . Of these patients, the 3 patients treated with neoadjuvant chemotherapy along with surgery and postoperative chemoradiation, had a local recurrence (patients 1, 3 and 6). The 3-year distant metastasis-free survival rate was 78%. Three patients (18%) with a T4b-stage tumour developed hematogenous metastases. After treatment describe above (Table 3) , 2 patients died and one patient is alive without disease.
Survival rates (Figure 3)
The median follow-up period was 39 months (range, 6 to 96 months). cific enolase (NSE), p53, chromogranin, and synaptophysin (3, 8) .
Vimentin, muscle markers (actins, desmins, myoglobin), hematolymphoyd markers (leucocyte common antigen, B and T-cell markers), melanocytic cell markers (melan A, HMB-45) and sar- . SNUC does not usually show recurrent cytogenetic changes. SNUC is typically negative for EBV. Small cohorts of patients demonstrated overexpression of p16 in the absence of high-risk human papillomavirus (HPV) (9) . However, recent studies have shown the presence of HPV DNA (10) .
Currently, decision making about the treatment of these tumours is based on the experience of several referral institutions and there is no consensus for the standard treatment of SNUC.
Given the low frequency of these tumours, the treatment of SNUC is challenging and it is difficult to design robust studies to test therapeutic protocols. Furthermore, the optimal order of treatment remains unclear. Despite multimodality therapy (2, (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , endorsed universally, the prognosis remains poor and 5-year OS rates range from 20% to 74% and the median survival time is less than 18 months (4, 10) . Table 4 illustrates a review of outcomes of case-series studies where patients with SNUC were treated with combined therapy.
Studies with at least 15 patients were included to draw consistent conclusions. Yoshida et al. (18) (2, 15, 20) . These findings suggest that, whenever feasible, gross total resection and post-operative chemoradiotherapy yielded the most favorable outcomes for SNUC. The best sequence of these modalities may be dictated by the performance status of the patient, extent of disease, and available treatment resources.
The meta-analyses of 167 patients performed by Reiersen et al. (5) found that patients who had surgery with the addition of radiation and/ or chemotherapy had a 260% increased chance of survival compared with those who had surgery alone (OR = 2.6; 95% CI, 0.82-7.87). The presence of neck metastases was also a poor prognostic sign.
To our knowledge, our report consists of one of the largest case series to analyse the outcomes after employing combined therapy. In our study, more than 90% of patients had T4-stage, Table 3 . Recurrence, treatment and outcomes.
S: surgery; CT: chemotherapy; PORT: postoperative radiotherapy; POCRT: postoperative chemo-radiotherapy; D: died; AWD: alive without disease.
C o r r e c t e d p r o o f
and 12 % of patients have a node-positive disease at diagnosis, as in most series (14) . Four distinct therapeutic regimens were employed but every patient in our cohort received RT (to the primary tumour and ENI). Fourteen patients (82%) underwent surgical extirpation of the tumour via craniofacial resection.
Of these patients, 5 were operated through an endoscopic approach. So far, only one previous series showed cases in which this approach was used, with success (21) . Choosing an endoscopic approach does not mean that a radical resection cannot be performed. One of these patients developed a distant metastasis and another developed local recurrence, but she presented initially with a very advanced tumour involving the brain.
Endoscopic surgery reduces the number of complications and morbidity due to surgery and it reduces possible complications due to RT after upfront open surgery. Moreover, due to the fact that resection of SNUC with wide margins is not always possible, either by open or endoscopic techniques, because it would affect cranial nerves, the eyes, internal carotid arteris or the brain, endoscopic surgery in SNUC could be offered in most patients (22) . The mainstay treatment used at our institution is craniofacial resection plus chemoradiotherapy (10 patients). In cases which respectability upfront is questionable, induction chemotherapy was considered to reduce the tumour size and therefore facilitates surgery. However, these cases carry a dismal prognosis. Despite aggressive multimodality management, calculated 5-year OS and DFS rates were 58% and 61%, respectively, similar to 5-year OS described in the literature (20-63%) (10) . Reiersen et al. (5) in a meta-analysis found a DFS rate of 26,3%. The 3-year local control rate was 76%, being 100% in the chemoradiotherapy group and 71% in surgery-based group. Similar results using definitive chemoradiation have been described by some authors (10, 17) , although differences were not significant. Sometimes non surgery-based treatment can lead to prolonged survival for patients with advanced disease. The inclusion in the surgical group of 3 patients with very advanced tumours, and the small number of patients will have limited this analysis. SNUC is reputed to be refractory to even the most radical therapy and to carry a poor prognosis, particularly when the tumour transgresses the 
Christopherson et al. (17) Musy et al.
Chen et al. (15) Jeng et al. (23) Tazler et al. LC: local control rate; OS: overall survival; DFS: disease free survival, § Present series.
*Only the series reported by Al -Mamgani (14) and Yoshida (18) showed a statistical difference in survival between the treatment groups favoring surgical-based treatment. (5, 17) . Elective neck irradiation seems mandatory in SNUC.
Up-front chemoradiotherapy was used in selected cases to minimize the complications of radical of surgical treatments. It is noteworthy that Musy et al. (2) found residual tumour in 70% of surgical specimens after primary chemoradiation. This suggests that resection should be considered as a essential part of therapy. Indeed, all survivors in the largest study of SNUC were treated with surgery as part of their management (23) . Moreover, gross total resection led to a superior control rate compared with subtotal resection (15) .
The use of chemotherapy in the treatment of SNUC is controversial and needs to be further explored. Adjuvant chemotherapy is sometimes used in an attempt to down-staging the tumour before surgical resection. Chemotherapy does not appear to improve the outcome in these patients because they likely have more advanced disease. Rischin et al. (13) suggested reducing the incidence of distant metastases using induction chemotherapy.
In our series, all patients who developed distant metastases were treated without induction chemotherapy and those who received chemotherapy, had very advanced tumours and died of locoregional disease.
An irradiation dose-response relationship might exist in case of SNUC (24) . Doses greater than 60 Gy seem to be more favourable in local control rates (14) . New radiation techniques as intensity-modulated RT (IMRT), volumetric-modulated arc therapy (VMAT), tomotherapy and proton therapy enable the achievement of sharp dose gradients near the targeted volumes (25) . The greater conformality afforded by these new techniques produces a lower rate of radiation-induced toxicity and increases therapeutic efficiency. With IMRT and VMAT, microscopic tumour spread cannot only be pursued around the primary site and through the lymphatic channels to the neck nodes, but also to other routes of dissemination. IMRT compared to 3DCRT, improved DFS and local control and decreased acute and late toxicity (14, 26) . We used IMRT with concurrent chemotherapy in only 3 patients after surgery. All of them are alive without disease and without treatment-related complications. A patient who developed cervical and distant metastasis was treated with VMAT and remains without disease. Other authors have employed proton beam radiation with high efficiency and low toxicity (10, 17) . Precision RT could be an important component in the treatment of these tumours, both the primary disease and the recurrence.
As is shown in the current study, local recurrence and distant metastases remain significant problems in patients with SNUC.
Highly conformal RT techniques and intensification of chemotherapeutic schedules should be implemented in the expectation of improving the outcomes (14) . Moreover, to understand the biological characteristics of SNUC and to develop novel alternative treatments, it is essential to establish a reliable and phenotypically accurate tumour model system for SNUC. However, attempts to understand the genetics and biology of SNUC and to identify molecular targets are restricted by a paucity of materials, cell lines and animal models (8) . Advances in cancer treatment, including the introduction of molecular targeted therapies (e.g. c-KIT overexpression without activating mutation) (27) , may yield significant improvements in the prognosis of patients with SNUC. Polymorphisms were noted within the promoter region of VEGF, which may merit future studies as predictive biomarkers for treatment response or overall survival (28) . Recently, Takahashi et al. (29) reported the establishment and characteriza- 
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